Your browser doesn't support javascript.
loading
Broadening the Spectrum of Ehlers Danlos Syndrome in Patients With Congenital Adrenal Hyperplasia.
Morissette, Rachel; Chen, Wuyan; Perritt, Ashley F; Dreiling, Jennifer L; Arai, Andrew E; Sachdev, Vandana; Hannoush, Hwaida; Mallappa, Ashwini; Xu, Zhi; McDonnell, Nazli B; Quezado, Martha; Merke, Deborah P.
Afiliação
  • Morissette R; Clinical Center (R.M., A.F.P., A.M., D.P.M.), National Institutes of Health, Bethesda, Maryland 20892-1932; PreventionGenetics (W.C.), Marshfield, Wisconsin 54449; Laboratory of Pathology (J.L.D., M.Q.), National Cancer Institute, and The Eunice Kennedy Shriver National Institute of Child Health and
  • Chen W; Clinical Center (R.M., A.F.P., A.M., D.P.M.), National Institutes of Health, Bethesda, Maryland 20892-1932; PreventionGenetics (W.C.), Marshfield, Wisconsin 54449; Laboratory of Pathology (J.L.D., M.Q.), National Cancer Institute, and The Eunice Kennedy Shriver National Institute of Child Health and
  • Perritt AF; Clinical Center (R.M., A.F.P., A.M., D.P.M.), National Institutes of Health, Bethesda, Maryland 20892-1932; PreventionGenetics (W.C.), Marshfield, Wisconsin 54449; Laboratory of Pathology (J.L.D., M.Q.), National Cancer Institute, and The Eunice Kennedy Shriver National Institute of Child Health and
  • Dreiling JL; Clinical Center (R.M., A.F.P., A.M., D.P.M.), National Institutes of Health, Bethesda, Maryland 20892-1932; PreventionGenetics (W.C.), Marshfield, Wisconsin 54449; Laboratory of Pathology (J.L.D., M.Q.), National Cancer Institute, and The Eunice Kennedy Shriver National Institute of Child Health and
  • Arai AE; Clinical Center (R.M., A.F.P., A.M., D.P.M.), National Institutes of Health, Bethesda, Maryland 20892-1932; PreventionGenetics (W.C.), Marshfield, Wisconsin 54449; Laboratory of Pathology (J.L.D., M.Q.), National Cancer Institute, and The Eunice Kennedy Shriver National Institute of Child Health and
  • Sachdev V; Clinical Center (R.M., A.F.P., A.M., D.P.M.), National Institutes of Health, Bethesda, Maryland 20892-1932; PreventionGenetics (W.C.), Marshfield, Wisconsin 54449; Laboratory of Pathology (J.L.D., M.Q.), National Cancer Institute, and The Eunice Kennedy Shriver National Institute of Child Health and
  • Hannoush H; Clinical Center (R.M., A.F.P., A.M., D.P.M.), National Institutes of Health, Bethesda, Maryland 20892-1932; PreventionGenetics (W.C.), Marshfield, Wisconsin 54449; Laboratory of Pathology (J.L.D., M.Q.), National Cancer Institute, and The Eunice Kennedy Shriver National Institute of Child Health and
  • Mallappa A; Clinical Center (R.M., A.F.P., A.M., D.P.M.), National Institutes of Health, Bethesda, Maryland 20892-1932; PreventionGenetics (W.C.), Marshfield, Wisconsin 54449; Laboratory of Pathology (J.L.D., M.Q.), National Cancer Institute, and The Eunice Kennedy Shriver National Institute of Child Health and
  • Xu Z; Clinical Center (R.M., A.F.P., A.M., D.P.M.), National Institutes of Health, Bethesda, Maryland 20892-1932; PreventionGenetics (W.C.), Marshfield, Wisconsin 54449; Laboratory of Pathology (J.L.D., M.Q.), National Cancer Institute, and The Eunice Kennedy Shriver National Institute of Child Health and
  • McDonnell NB; Clinical Center (R.M., A.F.P., A.M., D.P.M.), National Institutes of Health, Bethesda, Maryland 20892-1932; PreventionGenetics (W.C.), Marshfield, Wisconsin 54449; Laboratory of Pathology (J.L.D., M.Q.), National Cancer Institute, and The Eunice Kennedy Shriver National Institute of Child Health and
  • Quezado M; Clinical Center (R.M., A.F.P., A.M., D.P.M.), National Institutes of Health, Bethesda, Maryland 20892-1932; PreventionGenetics (W.C.), Marshfield, Wisconsin 54449; Laboratory of Pathology (J.L.D., M.Q.), National Cancer Institute, and The Eunice Kennedy Shriver National Institute of Child Health and
  • Merke DP; Clinical Center (R.M., A.F.P., A.M., D.P.M.), National Institutes of Health, Bethesda, Maryland 20892-1932; PreventionGenetics (W.C.), Marshfield, Wisconsin 54449; Laboratory of Pathology (J.L.D., M.Q.), National Cancer Institute, and The Eunice Kennedy Shriver National Institute of Child Health and
J Clin Endocrinol Metab ; 100(8): E1143-52, 2015 Aug.
Article em En | MEDLINE | ID: mdl-26075496
CONTEXT: The contiguous gene deletion syndrome (CAH-X) was described in a subset (7%) of congenital adrenal hyperplasia (CAH) patients with a TNXA/TNXB chimera, resulting in deletions of CYP21A2, encoding 21-hydroxylase necessary for cortisol biosynthesis, and TNXB, encoding the extracellular matrix glycoprotein tenascin-X (TNX). This TNXA/TNXB chimera is characterized by a 120-bp deletion in exon 35 and results in TNXB haploinsufficiency, disrupted TGF-ß signaling, and an Ehlers Danlos syndrome phenotype. OBJECTIVE: The objective of the study was to determine the genetic status of TNXB and resulting protein defects in CAH patients with a CAH-X phenotype but not the previously described TNXA/TNXB chimera. Design, Settings, Participants, and Intervention: A total of 246 unrelated CAH patients were screened for TNXB defects. Genetic defects were investigated by Southern blotting, multiplex ligation-dependent probe amplification, Sanger, and next-generation sequencing. Dermal fibroblasts and tissue were used for immunoblotting, immunohistochemical, and coimmunoprecipitation experiments. MAIN OUTCOME MEASURES: The genetic and protein status of tenascin-X in phenotypic CAH-X patients was measured. RESULTS: Seven families harbor a novel TNXB missense variant c.12174C>G (p.C4058W) and a clinical phenotype consistent with hypermobility-type Ehlers Danlos syndrome. Fourteen CAH probands carry previously described TNXA/TNXB chimeras, and seven unrelated patients carry the novel TNXB variant, resulting in a CAH-X prevalence of 8.5%. This highly conserved pseudogene-derived variant in the TNX fibrinogen-like domain is predicted to be deleterious and disulfide bonded, results in reduced dermal elastin and fibrillin-1 staining and altered TGF-ß1 binding, and represents a novel TNXA/TNXB chimera. Tenascin-X protein expression was normal in dermal fibroblasts, suggesting a dominant-negative effect. CONCLUSIONS: CAH-X syndrome is commonly found in CAH due to 21-hydroxylase deficiency and may result from various etiological mechanisms.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hiperplasia Suprarrenal Congênita / Síndrome de Ehlers-Danlos Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hiperplasia Suprarrenal Congênita / Síndrome de Ehlers-Danlos Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article